House legislation targets drug manufacturers and distributors

July 1999
New York Amsterdam News;07/29/99, Vol. 90 Issue 31, p6
Focuses on a United States legislation aimed at creating and enforcing the responsibility imposed on drug manufacturers and distributors. Amendment to the Consequences for Juvenile Offenders Act; Role played by Congresswoman Maxine Walters in the successful passage of the bill.


Related Articles

  • Pharmacies May Be Liable For Overdose. MACK, DEBBI // Corporate Legal Times;Sep2005, Vol. 15 Issue 166, p79 

    Reports on a Florida state appeals court ruling on a case citing that a widower could bring a negligence suit against the pharmacies that sold his wife the prescription drugs that caused her fatal overdose. Details about the case; Issues on consumer protection and drug safety; Pharmaceutical laws.

  • FDA Scrutiny on Ads That Tout Illegal Drug Imports. Melillo, Wendy // Adweek Eastern Edition;3/17/2003, Vol. 44 Issue 11, p9 

    Reports on U.S. Food and Drug Administration's scrutiny on advertisings (ad) that tout illegal drug imports, by extending the liability to advertising agencies that prepare the ads and the media outlets that carry them. Laws violated by the import of prescription drugs from Canada; Appearance...

  • Pure Consumption Cases under the Federal "Crackhouse" Statute. Rayfield, Michael E. // University of Chicago Law Review;Fall2008, Vol. 75 Issue 4, p1805 

    The article reports on how circuit courts can determine the defendant's purpose in maintaining a place for drug activities that is sufficient for criminal liability under the statute against pure consumption cases. The circuit courts can determine the purpose of maintaining a place through his...

  • Texas Sets Pace in Drug Tort Reform. Cohen, Joseph // Drug Discovery & Development;Jun2004, Vol. 7 Issue 6, p15 

    Focuses on the role of the state of Texas in critical pre-trial activities in mass tort litigation in the pharmaceutical industry in the U.S. Description of the legislature in the state; Adoption of U.S. Food and Drug Administration warnings defense by the state; Importance of legislative...

  • J&J expected to offer $4B settlement for hip implant lawsuits. Lee, Jaimy // Modern Healthcare;11/18/2013, Vol. 43 Issue 46, p4 

    The article informs that Johnson & Johnson is expected to announce a four billion U.S. dollar settlement to resolve thousands of lawsuits filed in response to the company's recalled metal-on-metal hip implants. It informs that the ASR hip implants have failed at higher rates than traditional...

  • Chemo reimbursement cuts may have profound effect. Gatty, Bob // Urology Times;Apr2004, Vol. 32 Issue 5, p82 

    Discusses how physicians who administer chemotherapy drugs in their practices must cope with reimbursement reductions imposed by the U.S. Medicare reform law. Senate's failure to invoke cloture on legislation limiting the medical liability awards that injured patients may receive for obstetric...

  • Evidence Matters: Other Injuries, Accidents, and Complaints in Product Liability Litigation. Day, Jones // Venulex Legal Summaries;2008 Q1, p1 

    The article stresses that evidence of other injuries, accidents and complaints plays a role when individuals file suit against manufacturers for allegedly obtaining injuries from use of the company's product. It states, however, that this is especially so in today's mass-produced consumer...

  • Autoridades reguladoras de medicamentos sul-americanas: uma análise a partir de regras organizacionais. Martins da Silva Sandri, Mariane; Horsth De Seta, Marismary; Lucia Luiza, Vera // Revista Panamericana de Salud Publica;2013, Vol. 34 Issue 3, p169 

    Objective. To describe the organization of national drug regulatory authorities (DRAs) in Argentina, Brazil, Chile, and Peru through the analysis of categories representing organizational rules. Methods. The DRAs were selected using the following criteria: being in a South American country,...

  • J&J mulling $3 billion hip implant settlement.  // Medical Device Daily;8/23/2013, Vol. 17 Issue 163, p2 

    The article reports on the consideration by multinational medical devices, pharmaceutical and consumer packaged goods manufacturer Johnson & Johnson (J&J) paying more than 3 billion U.S. dollars to settle lawsuits over its recalled hip implants.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics